SARS-CoV-2 ORF1ab polyprotein (3326-3340)

NHNFLVQAGNVQLRV-acid

  • Description

  • Application Data

Description

The SARS-CoV-2 ORF1ab polyprotein sequence NHNFLVQAGNVQLRV (3326-3340) has been identified as an epitope for anti-viral targeting.

See full description

Application Data

Catalogue number crb1001828
Molecular Weight 1707.9
Sequence (one letter code)

NHNFLVQAGNVQLRV-acid

Sequence (three letter code)

H-Asn-His-Asn-Phe-Leu-Val-Gln-Ala-Gly-Asn-Val-Gln-Leu-Arg-Val-OH

Purity >95%
Storage -20°C
References

Gustiananda et al., (2021). Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population. Vaccines, 9(12): 1459. doi: 10.3390/vaccines9121459.

Stolp et al., (2022). SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models. Cell Reports, 38(7): 110387. doi: 10.1016/j.celrep.2022.110387.

Manufactured in: United Kingdom
Data Sheet Data Sheet Data Sheet Material Safety Data Sheet (MSDS)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 non-structural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. SARS-CoV-2 non-structural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. These factors make ORF1ab polyprotein a good target for developing new antiviral drugs. In addition, the identification of epitopes within the ORF1ab polyprotein sequence can help design more effective SARS-CoV-2 vaccines.

Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. ORF1ab polyprotein (3326-3340) is an epitope candidate with various HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.

SARS-CoV-2 ORF1ab polyprotein (3326-3340)

Cat No.Pack SizePriceQty.
0.5mg£95.00
1mg£130.00
Bulk Quote